For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.
The global partner of choice for companion diagnostics, we help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value predictive assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.